Introduction

Materials and methods
Mitoxantrone (Novantrone; dihydroxyanthracenedione) is one of the anthracenedione derivatives synthesized in an attempt to find an agent with the same or better antitumor activity than adriamycin without its dose-limiting cardiotoxicity [1, 2] . Phase I studies showed mitoxantrone to be well tolerated with reversible myelosuppression as its dose-limiting toxicity [3] . Its antitumor activity has been similar to adriamycin. In order to insure an appropriate distribution of untreated patients on Phase II trials in advanced pancreatic cancer, the Southwest Oncology Group initiated a series of randomized Phase II trials. We report a trial of mitoxantrone in advanced adenocarcinoma of the pancreas.
Previously untreated patients were randomized to a combination of fluorouracil, adriamycin, mitomycin and streptozotocin (FAM-S) or to mitoxantrone as a single agent. At relapse or disease progression patients who still met eligibility requirements were reregistered and crossed over to the other arm.
Patient eligibility included histologic confirmation of adenocarcinoma of the pancreas not amenable to curative surgery or radiation; objective measurable disease; a life expectancy of at least six weeks; a performance status of three or better by SWOG criteria; WBC count _> 3500/mm3; a platelet count of ~ 125,000 mm 3, a serum creatinine _< 2.0 mg%. There were no age restrictions. Patients had received no chemotherapy except at cross-over. At cross-over patients had recovered from any acute toxicities and had received no chemotherapy for six weeks. Patients with past or present history of congestive heart failure were not eligible. In pa-tients with recent abdominal surgery, treatment was held for 3 weeks or until recovery of bowel function, whichever occurred later. Concomitant radiation therapy was allowed for painful boney metastases only. Patients were stratified by performance status (0-1 vs 2-3) and according to whether biopsy only or palliative bypass procedures were performed.
During treatment, weekly complete blood counts, WBC and differentials, and platelets were monitored. Tumor measurements, kidney and liver function tests, EKG's, and performance status were obtained prior to each course.
Cardiac ejection fractions determined by gated radionuclide angiography were obtained in all patients pretreatment and monitored thereafter in those patients who had received their maximal dose of adriamycin or who had received mitoxantrone for six weeks or more.
Doses of mitoxantrone were adjusted for hepatic function. The initial dose of mitoxantrone for patients with a bilirubin _< 1.5 rag% (good risk) was 12 mg/m 2 given as a 30 minute infusion in 100 cc of DsW through a freely running intravenous line. Patients with an abnormal bilirubin were considered as poor risk and treated with reduced doses. Patients with a bilirubin between 1.5-3.0 rag% received 6 mg/m 2 and patients with a bilirubin of greater than 3 rag% received 4.5 mg/m 2. The treatment was repeated every three weeks provided the patient had recovered from previous drug induced toxicity. Doses for subsequent courses were adjusted based upon previous drug induced toxicity. Patients without side-effects (WBC _> 4000/mm 3, Platelets ~ 100,000/mm 3) had their doses increased by 10%. Patients with WBC 2000-3900/ mm 3 or platelets 50,000-90,000/mm 3 which had resolved at 3 weeks received the same dose. Patients with WBC 1000-1900/mm 3 or platelets 25,000-49,900/mm 3 or requiring more than 1 week to recover had their dose reduced by 17%. Patients with life threatening toxicity (WBC < 1000/ram 3, platelets < 25,000/m 3) had their dose reduced by 50%.
Response and survival duration were calculated from the initial date of treatment. Complete remission was defined as complete disappearance of all clinical evidence of tumor for a minimum of four weeks. Partial remission was defined as 50% or greater decrease in the sum of the products of all diameters of measured lesions with no new disease or increase in size of any lesion. Progression was defined as the unequivocal increase of at least 25% in the size of any measurable lesion or the appearance of new lesions.
Results
Thirty-six patients were registered on study. All patients were eligible and all were evaluated. Patient characteristics are presented in Table 1 . Twenty-four previously untreated good risk patients were evaluable and received mitoxantrone at 12 mg/m 2. Three patients had stable disease for 73, 195 and 233 days. Twenty-one patients had progressive disease with two early disease related deaths (days 3 and 8).
Five untreated poor risk patients received reduced doses of mitoxantrone (3 at 4.5 mg/m 2 level and 2 at 6.0 mg/m 2 level). There were no objective responses. There was one early death due to disease at day 14. The survival curves for these two groups of patients (good and poor risk previously untreated) are shown on Fig. 1 . Seven patients were randomized to mitoxantrone after failing FAM-S. Three good risk patients received eight courses at 12 mg/m 2. One patient treated with 6 mg/m 2 was lost to follow up and the second patient died day seven due to disease. One patient was treated with 4.5 mg/m 2 and expired after one course. One patient was treated with only 3 mg/m 2 due to dose reduction error. She expired on day three. There were no objective responses.
Toxicity
Myelosuppression in the form of leukopenia was the major toxicity in the good risk group. Forty-two courses at the 12 mg/m 2 dose were evaluable for myelosuppression. The median leukocyte nadir for this group was 2300/mm 3 (Range 500-> 20,000). The median platelet nadir was > 150,000/mm 3. One patient with concomitant sepsis had a platelet count of 24,000/mm 3. Drops in hemoglobin (1-3 grams) without documented bleeding were seen in 5 patients. Two patients required dose reductions of 10% in seven courses. Dose escalation by 10% was required in two patients. Leukocyte counts of 2,999 (1000 granulocytes) or less were observed in 72% of the courses. Mild nausea, vomiting and alopecia were observed. There were no treatment related deaths.
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Myelosuppression was minimal in the poor risk patients treated. Two courses of six were not evaluable for hematologic toxicity due to early death. The median leukocyte nadir was > 4000/mm 3. The platelet nadir was _> 100,000/mm 3. One patient had an unexplained 2 gram drop in hemoglobin. Two patients had mild nausea and vomiting.
In the cross-over group receiving mitoxantrone as second line therapy, toxicity was poorly documented. Ten courses were not evaluable for hematologic toxicity (one patient was lost to follow up, and there were three early deaths). In the two courses for which hematologic data was available, there was no myelosuppression.
Cardiac toxicity was difficult to assess due to the limited number of patients who received significant cumulative doses. Five good risk patients received four or more courses of mitoxantrone with no change in ejection fractions by gated radionuclide angiography. One patient experienced an episode of paroxysmal atrial tachycardia between courses three and four. This was not temporally related to her treatment and did not require hospitalization. There was no other clinical or EKG evidence of cardiotoxicity.
Conclusion
Mitoxantrone was well tolerated, but showed no objective responses in this group of patients, which included twenty-four previously untreated individuals who received adequate doses of drug. The 95~ confidence level for this group of patients is 0-14. 3~ We conclude that mitoxantrone, administered at 12 mg/m 2 every 3 weeks has no activity in advanced adenocarcinoma of the pancreas.
